Table 4.
The use of neoadjuvant systemic therapy by country
| Characteristic | Austria, N = 29a | Germany, N = 31a | Hungary, N = 99a | Italy, N = 2a | Lithuania, N = 4a | Switzerland, N = 335a | p-valueb |
|---|---|---|---|---|---|---|---|
| Neoadjuvant treatment administered | 16 (55.2%) | 8 (25.8%) | 18 (18.2%) | 2 (100.0%) | 1 (25.0%) | 120 (35.8%) | < 0.001 |
| Chemotherapy | 11 (37.9%) | 7 (22.6%) | 17 (17.2%) | 2 (100.0%) | 1 (25.0%) | 113 (33.7%) | 0.004 |
| Endocrine therapy | 5 (17.2%) | 1 (3.2%) | 1 (1.0%) | 0 (0.0%) | 0 (0.0%) | 17 (5.1%) | 0.033 |
| Immunotherapy | 5 (17.2%) | 2 (6.5%) | 3 (3.0%) | 2 (100.0%) | 0 (0.0%) | 30 (9.0%) | 0.003 |
| No neoadjuvant therapy | 13 (44.8%) | 23 (74.2%) | 81 (81.8%) | 0 (0.0%) | 3 (75.0%) | 215 (64.2%) | < 0.001 |
an (%)
bFisher’s exact test